Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.45 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161302 | 0.91 | NPC1 (0.53) | NPC1KDM4ERAB9APKMALDH1A1 | |
| SCHEMBL162514 | 0.86 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL161164 | 0.86 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL27911962 | 0.85 | NPC1 (0.56) | NPC1KDM4ERAB9APKMALDH1A1 | |
| SCHEMBL161659 | 0.78 | PTPN1 (0.48) | DGAT1 | |
| SCHEMBL163250 | 0.77 | DGAT1 (0.54) | LMNADGAT1 | |
| SCHEMBL162708 | 0.76 | PTPN1 (0.50) | DGAT1 | |
| SCHEMBL165688 | 0.76 | DGAT1 (0.60) | DGAT1 | |
| SCHEMBL162199 | 0.76 | ALDH1A1 (0.42) | KDM4EALDH1A1LMNADGAT1ROCK2 | |
| SCHEMBL162111 | 0.75 | RAB9A (0.46) | NPC1RAB9AALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103228633-A | Heterocyclic compounds as DGAT1 inhibitors | PIRAMAL LIFE SCIENCES LTD | 2013-07-31 | — | — | CN | claimed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| CN-103228633-A | Heterocyclic compounds as DGAT1 inhibitors | PIRAMAL LIFE SCIENCES LTD | 2013-07-31 | — | — | CN | disclosed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | NPC1 86/4885KDM4E 4508/4885RAB9A 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.